THE Philippine Government has suspended use of Sanofi's dengue virus vaccine, amid growing public anger at warnings from the company that some people could face significant adverse events.
Dengvaxia has been administered to more than 800,000 school children, but late last month Sanofi released new data showing the drug could lead to "severe infections" for vaccinated people not previously infected.
Sanofi has urged the Philippines to lift the suspension of the drug, insisting it is safe and effective for most people.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Dec 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Dec 17